China Medical System Wins NMPA Nod for Novel Obesity Drug Trials

China Medical System Holdings ( (HK:0867) ) has shared an announcement.

China Medical System Holdings has received approval from China’s National Medical Products Administration to begin clinical trials of its self-developed siRNA injection CMS-D008 for overweight and obese patients. The novel therapy targets the INHBE gene in the liver to reduce Activin E levels, aiming to cut fat mass while preserving muscle and potentially offering durable, high-quality weight loss and metabolic benefits.

The company plans to position CMS-D008 as a differentiated obesity treatment that complements its GLP-1R/GCGR dual agonist CMS-D005, with the two candidates expected to deliver synergistic weight-loss and liver-fat reduction effects. Management says it will accelerate R&D and future commercialization using its existing cardiovascular and metabolic network, reinforcing its competitive standing in the fast-growing obesity and metabolic treatment market and signaling potential long-term upside for patients and investors if trials succeed.

The most recent analyst rating on (HK:0867) stock is a Buy with a HK$17.00 price target. To see the full list of analyst forecasts on China Medical System Holdings stock, see the HK:0867 Stock Forecast page.

More about China Medical System Holdings

China Medical System Holdings is a pharmaceutical group focused on developing and commercializing innovative therapies, particularly in cardiovascular and metabolic diseases. Leveraging an established network and R&D platform in China, the company is expanding its pipeline in obesity and related metabolic conditions through self-developed, cutting-edge drug candidates.

Average Trading Volume: 3,973,749

Technical Sentiment Signal: Buy

Current Market Cap: HK$34.54B

See more insights into 0867 stock on TipRanks’ Stock Analysis page.